Personas / Equipo Humano

Emma Barroso Fernández

Buscador de publicaciones

Publicaciones

  • Serrano-Marco L, Chacón MR, Maymó-Masip E, Barroso E, Salvadó L, Wabitsch M, Garrido-Sánchez L, Tinahones FJ, Palomer FX, Vendrell J and Vazquez M.

    TNF-a inhibits PPARß/d activity and SIRT1 expression through NF-?B in human adipocytes.

    BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS . 1821(9): 1177-1185. Nº de citas: 45

    [doi:10.1016/j.bbalip.2012.05.006]

  • Serrano-Marco L, Barroso E, El Kochairi I, Palomer FX, Michalik L, Wahli W and Vazquez M.

    The peroxisome proliferator-activated receptor (PPAR) ß/d agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells.

    Diabetologia . 55(3): 743-751. Nº de citas: 62

    [doi:10.1007/s00125-011-2401-4]

  • Salvadó L, Serrano-Marco L, Barroso E, Palomer FX and Vazquez M.

    Targeting PPARß/d for the treatment of type 2 diabetes mellitus.

    EXPERT OPIN THER TAR . 16(2): 209-223. Nº de citas: 31

    [doi:10.1517/14728222.2012.658370]

  • Barroso E, Rodríguez-Calvo R, Serrano-Marco L, Astudillo AM, Balsinde J, Palomer FX and Vazquez M.

    The PPARß/d activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1a-Lipin 1-PPARa pathway leading to increased fatty acid oxidation.

    Endocrinology . 152(5): 1848-1859. Nº de citas: 127

    [doi:10.1210/en.2010-1468]

  • Barroso E, Eyre E, Palomer FX and Vazquez M.

    The peroxisome proliferator-activated receptor ß/d (PPARß/d) agonist GW501516 prevents TNF-a-induced NF-?B activation in human HaCaT cells by reducing p65 acetylation through AMPK and SIRT1.

    BIOCHEMICAL PHARMACOLOGY . 81(4): 534-543. Nº de citas: 62

    [doi:10.1016/j.bcp.2010.12.004]

  • Coll T, Barroso E, Alvarez-Guardia D, Serrano L, Salvadó L, Merlos M, Palomer FX and Vazquez M.

    The Role of Peroxisome Proliferator-Activated Receptor beta/delta on the Inflammatory Basis of Metabolic Disease.

    PPAR Research . 2010: . Nº de citas: 22

    [doi:10.1155/2010/368467]

  • Coll T, Alvarez-Guardia D, Barroso E, Gómez-Foix AM, Palomer FX, Laguna JC and Vazquez M.

    Activation of peroxisome proliferator-activated receptor-{delta} by GW501516 prevents fatty acid-induced nuclear factor-{kappa}B activation and insulin resistance in skeletal muscle cells.

    Endocrinology . 151(4): 1560-1569. Nº de citas: 74

    [doi:10.1210/en.2009-1211]

  • Coll T, Rodrïguez-Calvo R, Barroso E, Serrano L, Eyre E, Palomer FX and Vazquez M.

    Peroxisome proliferator-activated receptor (PPAR) beta/delta: a new potential therapeutic target for the treatment of metabolic syndrome.

    Current Molecular Pharmacology . 2(1): 46-55.

  • Rodríguez-Calvo R, Barroso E, Serrano L, Coll T, Sánchez RM, Merlos M, Palomer FX, Laguna JC and Vazquez M.

    Atorvastatin prevents carbohydrate response element binding protein activation in the fructose-fed rat by activating protein kinase A.

    HEPATOLOGY . 49(1): 106-115. Nº de citas: 57

    [doi:10.1002/hep.22570]

  • Rodríguez-Calvo R, Serrano L, Barroso E, Coll T, Palomer FX, Camins A, Sánchez RM, Alegret M, Merlos M, Pallàs M, Laguna JC and Vazquez M.

    Peroxisome proliferator-activated receptor alpha down-regulation is associated with enhanced ceramide levels in age-associated cardiac hypertrophy.

    JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES . 62(12): 1326-1336. Nº de citas: 22

    [doi:10.1093/gerona/62.12.1326]